Company Overview and News

 
Risk of order book reductions seen with infrastructure job cuts

2018-10-05 theedgemarkets
Construction sector Maintain neutral: The outlook for the construction sector remains challenging as the federal government is reviewing ongoing infrastructure projects to reduce costs by 20%-33%. Projects that could be affected include the Klang Valley mass rapid transit Line 2 (MRT2) and light rail transit Line 3 (LRT3), Pan Borneo Highway (PBH) and Gemas-Johor Baru Electrified Double Tracking (EDT).
2852 9261 3204 5226 6238 5924 5263 5054 9679 5085 7078

 
Leasing challenge for TRX

2018-09-22 thestar.com.my
Asking price: The initial asking rent of RM17 per sq ft sought by Exchange 106 may come down to between RM11 and RM12 per sq ft. However, Lombardo (pic, below) is keeping mum on his asking rent for the Lifestyle Quarter.
9261 9679

 
Gadang shares rise on RM86mil contract win

2018-08-21 thestar.com.my
KUALA LUMPUR: Gadang Holdings Bhd ’s shares were strong in early trade jumping over 3% on news the firm secured a RM86mil contract.
9261

 
Trading ideas: Eita, Gadang, E&O, Velesto Energy, Amway, Perak Transit

2018-08-21 thestar.com.my
KUALA LUMPUR: Eita Resources Bhd , Gadang Holdings Bhd , Eastern and Oriental Bhd (E&O), Velesto Energy Bhd , Amway (M) Holdings Bhd amd Perak Transit Bhd are among the stocks to watch, according to JF Apex Research.
9261 5208

 
Gadang Holdings bags RM86mil TRX job

2018-08-21 thestar.com.my
KUALA LUMPUR: Gadang Holdings Bhd has bagged an RM86.09mil project from TRX City Sdn Bhd for the construction and completion of public realm works (Phase 1) at the Tun Razak Exchange.
9261 BSMAF 1818

 
Utusan, Petrol One, Eita Resources, Gadang, Dayang Enterprise, PetDag, Allianz, United Plantations, E&O, Velesto Energy, Amway and Rex Industry

2018-08-20 theedgemarkets
KUALA LUMPUR (Aug 20): Based on corporate announcements and news flow today, companies in focus on Tuesday (Aug 21) may include the following: Utusan Melayu (Malaysia) Bhd, Petrol One Resources Bhd, Eita Resources Bhd, Gadang Holdings Bhd, Dayang Enterprise Holdings Bhd, Petronas Dagangan Bhd, Allianz Malaysia Bhd, United Plantations Bhd, Eastern and Oriental Bhd (E&O), Velesto Energy Bhd, Amway (Malaysia) Holdings Bhd and Rex Industry Bhd.
9261 UPBMF 5681 5141 7027 1163 2089 5754 5209 5208 9946 BSMAF 1818

 
Gadang wins TRX contract worth RM86m

2018-08-20 theedgemarkets
KUALA LUMPUR (Aug 20): Gadang Holdings Bhd has secured a contract worth RM86.09 million to construct and complete the public realm works (Phase 1) of the Tun Razak Exchange (TRX).
9261

 
Gadang expected to do more aggressive marketing in property

2018-07-27 theedgemarkets
Gadang Holdings Bhd (July 26, 76.5 sen) Maintain buy with an unchanged target price (TP) of RM1.21: Gadang Holdings Bhd reported RM23.3 million net profit and RM182 million revenue in the fourth quarter of financial year 2018 (4QFY18) with net profit down 7% quarter-on-quarter (q-o-q) and 22% year-on-year (y-o-y).
9261

 
Gadang 4Q profit down; company pays 3 sen dividend

2018-07-26 theedgemarkets
KUALA LUMPUR: Gadang Holdings Bhd posted a 21.7% drop in net profit to RM23.27 million in the fourth financial quarter ended May 31, 2018 (4QFY18) from RM29.73 million a year ago, on poorer construction earnings, mitigated by stronger property profits.
9261

 
KLCI to extend gains, immediate support at 1,745

2018-07-25 theedgemarkets
KUALA LUMPUR (July 26): The FBM KLCI is expected to edge higher today in line with the extended rally at most global markets, with immediate support at 1,745.
9261 6084 5180 4723 5246 MGFCF

 
Westports, Star Media, JAKS, Cuscapi, Uzma, Marine & General, Vizione, D’nonce Tech, CMMT, Gadang, M-Mode and Mega First

2018-07-25 theedgemarkets
KUALA LUMPUR (July 25): Based on corporate announcements and news flow today, companies that may be in focus on Thursday (July 26) may include the following: Westports Holdings Bhd, Star Media Group Bhd, JAKS Resources Bhd, Cuscapi Bhd, Uzma Bhd, Marine & General Bhd, Vizione Holdings Bhd, D’nonce Technology Bhd, Capitaland Malaysia Mall Trust, Gadang Holdings Bhd, M-Mode Bhd and Mega First Corporation Bhd.
9261 6084 5180 4723 5246 BSMAF MGFCF 1818

 
Lower contribution from construction dampen Gadang's 4Q profit; declares 3 sen dividend

2018-07-25 theedgemarkets
KUALA LUMPUR (July 25): Gadang Holdings Bhd posted a 21.72% drop in net profit to RM23.27 million in the fourth quarter ended May 31, 2018 from RM29.73 million a year ago, on poorer construction earnings, mitigated by stronger property profits.
9261

 
Challenging outlook seen for construction in 2H18

2018-07-18 theedgemarkets
Construction sector Maintain neutral: Post-14th general election, the new Pakatan Harapan government embarked on a review of all megaprojects, as promised in its election manifesto. The Kuala Lumpur-Singapore high-speed rail (RM60 billion to RM70 billion) and mass rapid transit Line 3 (MRT3) (RM40 billion) were shelved shortly thereafter. Although there were reports regarding the revival of these projects, we reckon that chances are slim in the near term.
9261 5843 3204 5797 5072 7014 9679 7078 5056

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...